LOS ANGELES, CA / ACCESSWIRE / April 2, 2018 / Applied Biosciences Corp. (OTC:APPB), formerly known as Stony Hill Corp., a diversified cannabinoid therapeutics company focused on the medical, bioceutical and pet health industries, announced today that it has received notice of approval regarding the Company's previously announced name change. In addition to the name change, the Financial Industry Regulatory Authority (FINRA) has approved 'APPB' as the Company's new ticker symbol.
Applied Biosciences better aligns the direction and strategy of the Company with the key values and mission of its founders and strategic partners.
Chris Bridges, President of Applied Biosciences stated, "Today marks an important step forward for the company. As we continue to attract highly respected scientists, researchers and doctors to our Company and Advisory board, it is important that our corporate messaging and brand reflects our mission to leverage scientific research and studies to create products that promote healing, health and wellness. We are continuing to innovate and develop new products, in collaboration with our partners, that our customers can trust and rely upon, knowing that every product is tested and held to the highest quality standard in the industry."
About Applied Biosciences Corp.
Applied Biosciences Corp. (www.appliedbiocorp.com), is a diversified company focused on multiple areas of the medical, bioceutical, hemp and CBD industry. As a leading company in the CBD and Pet health space, the company is currently we are shipping to the majority of US states as well as to 5 International countries. The company is focused on select investment, consumer brands, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.
The company has several strategic partnerships and investments currently in place and is actively pursuing additional partnerships and strategic growth opportunities.
Except for historical information contained herein, statements in this release may be forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Applied Biosciences Corp. (the "Company") or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the Company's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors, including those described above and those risks discussed from time to time in the Company's filings with the Securities and Exchange Commission. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as (i) the development and protection of our brands and other intellectual property, (ii) the need to raise capital to meet business requirements, (iii) significant fluctuations in marketing expenses, (iv) the ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of our products and services, (v) the Company's ability to conduct the business if there are changes in laws, regulations, or government policies related to cannabis, (vi) management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and (vii) other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.